{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:08:17Z","timestamp":1765609697058},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T00:00:00Z","timestamp":1463529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00408-016-9898-8","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T06:50:12Z","timestamp":1463554212000},"page":"605-611","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism"],"prefix":"10.1007","volume":"194","author":[{"given":"Anish","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amishi","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Calixte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malaygiri","family":"Aparnath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Hindenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Salzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P.","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,18]]},"reference":[{"key":"9898_CR1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1055\/s-0037-1613887","volume":"83","author":"E Oger","year":"2000","unstructured":"Oger E (2000) Incidence of venous thromboembolism: a community-based study in western France. Thromb Haemost 83:657\u2013660","journal-title":"Thromb Haemost"},{"key":"9898_CR2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1525-1497.2006.00458.x","volume":"21","author":"FA Spencer","year":"2006","unstructured":"Spencer FA, Emery C, Lessard D et al (2006) The Worcester venous thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 21:722\u2013727","journal-title":"J Gen Intern Med"},{"key":"9898_CR3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood.V106.11.910.910","volume":"106","author":"JA Heit","year":"2005","unstructured":"Heit JA, Cohen AT, Anderson FA Jr (2005) Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 106:910","journal-title":"Blood"},{"issue":"9162","key":"9898_CR4","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0140-6736(98)07534-5","volume":"353","author":"SZ Goldhaber","year":"1999","unstructured":"Goldhaber SZ, Visani L, De Rosa M (1999) Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353(9162):1386\u20131389","journal-title":"Lancet"},{"issue":"8791","key":"9898_CR5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(92)91054-C","volume":"339","author":"P Prandoni","year":"1992","unstructured":"Prandoni P, Lensing AW, B\u00fcller HR et al (1992) Comparison\u00a0of\u00a0subcutaneous\u00a0low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339(8791):441\u2013445","journal-title":"Lancet"},{"issue":"10","key":"9898_CR6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJM199709043371001","volume":"337","author":"The Columbus Investigators","year":"1997","unstructured":"The Columbus Investigators (1997) Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 337(10):657\u2013662","journal-title":"N Engl J Med"},{"issue":"24","key":"9898_CR7","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342\u20132352","journal-title":"N Engl J Med"},{"issue":"14","key":"9898_CR8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR B\u00fcller","year":"2012","unstructured":"EINSTEIN\u2013PE Investigators, B\u00fcller HR, Prins MH, Lensin AW et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287\u20131297","journal-title":"N Engl J Med"},{"issue":"26","key":"9898_CR9","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499\u20132510","journal-title":"N Engl J Med"},{"issue":"9","key":"9898_CR10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"AMPLIFY Investigators, Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799\u2013808","journal-title":"N Engl J Med"},{"issue":"10","key":"9898_CR11","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3111\/13696998.2014.946993","volume":"17","author":"BK Bookhart","year":"2014","unstructured":"Bookhart BK, Haskell L, Bamber L et al (2014) Length of stay and economic consequences with rivaroxaban vs enoxaparin\/vitamin K antagonist in patients with DVT and PE: findings from the north American EINSTEIN clinical trial program. J Med Econ 17(10):691\u2013695","journal-title":"J Med Econ"},{"issue":"5","key":"9898_CR12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1185\/03007995.2013.879439","volume":"30","author":"B Bellen Van","year":"2014","unstructured":"Van Bellen B, Bamber L, Correa de Carvalho F et al (2014 May) Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 30(5):829\u2013837","journal-title":"Curr Med Res Opin"},{"key":"9898_CR13","unstructured":"Hospital adjusted expenses per inpatient day (2013) The Henry J. Kaiser Family Foundation"},{"key":"9898_CR14","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/j.1538-7836.2010.03989.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Anderson DR, Bungard TJ et al (2010) Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost 8:2192\u20132200","journal-title":"J Thromb Haemost"},{"key":"9898_CR15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1161\/STROKEAHA.110.592907","volume":"42","author":"JM Catherine","year":"2011","unstructured":"Catherine JM, Ciarametaro M, Hahn B et al (2011) Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 42:112\u2013118","journal-title":"Stroke"},{"issue":"4","key":"9898_CR16","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1160\/TH13-03-0243","volume":"110","author":"L Bamber","year":"2013","unstructured":"Bamber L, Wang MY, Prins MH et al (2013) Patient-reported treatment\u00a0satisfaction\u00a0with oral\u00a0rivaroxaban\u00a0versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 110(4):732\u2013741","journal-title":"Thromb Haemost"},{"issue":"2","key":"9898_CR17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.18553\/jmcp.2014.20.2.174","volume":"20","author":"J Lin","year":"2014","unstructured":"Lin J, Lingohr-Smith M, Kwong WJ (2014 Feb) Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a US payer perspective. J Manag Care Pharm 20(2):174\u2013186","journal-title":"J Manag Care Pharm"},{"issue":"2_Suppl","key":"9898_CR18","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","volume":"141","author":"GH Guyatt","year":"2012","unstructured":"Guyatt GH, Akl EA, Crowther M et al (2012) Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2_Suppl):7S\u201347S","journal-title":"Chest"},{"key":"9898_CR19","unstructured":"Specifications manual for national hospital inpatient quality measures discharges 01-01-15 (1Q15) through 09-30-15 (3Q15). Version 4.4"},{"issue":"14","key":"9898_CR20","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","volume":"124","author":"ES Eerenberg","year":"2011","unstructured":"Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011 Oct 4) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573\u20131579","journal-title":"Circulation"},{"issue":"2","key":"9898_CR21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","volume":"108","author":"R Marlu","year":"2012","unstructured":"Marlu R, Hodaj E, Paris A et al (2012 Aug) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108(2):217\u2013224","journal-title":"Thromb Haemost"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-016-9898-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00408-016-9898-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-016-9898-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T22:38:48Z","timestamp":1656110328000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00408-016-9898-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,18]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["9898"],"URL":"https:\/\/doi.org\/10.1007\/s00408-016-9898-8","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,18]]}}}